Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543.
Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543.
Trends Immunol. 2020 Nov;41(11):1006-1022. doi: 10.1016/j.it.2020.09.004. Epub 2020 Sep 17.
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics.
2019 年冠状病毒病仍然是一个主要的公共卫生关注点。中和抗体（nAbs）代表了一种前沿的抗病毒策略。我们在这里重点关注严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 SARS-CoV，并讨论针对猖獗的 SARS-CoV-2 感染的抗体研究的最新进展。我们提供了 SARS-CoV-2 衍生的 nAbs 的机制的观点，将这些与现有的 SARS-CoV 衍生的抗体进行比较。我们通过分析可用的刺突（S）糖蛋白-抗体复合物结构，深入了解这些抗体如何发生交叉反应和交叉中和。我们还提出了采用基于抗体的策略的方法，例如针对 SARS-CoV-2 的鸡尾酒抗体疗法，以克服目前鉴定的突变体的可能抗性，并减轻可能的抗体依赖性增强（ADE）病理学。本综述为针对 SARS-CoV-2 以及可能针对未来冠状病毒大流行的抗体和疫苗设计的进展提供了一个平台。
Zotero 插件
